The impact of drug pricing and reimbursement on the pharmaceutical industry
A recent survey for GlobalData’s “State of the Biopharmaceutical Industry 2025” report, conducted at the end of 2024, found drug…
All articles by
-
-
Obesity therapies and the multi-indication momentum: how industry is responding
The obesity therapeutics market has gone from a standing start to the story of the year in biopharmaceuticals - and…
-
Reducing patient burden in rare disease trials: DCTs for increased patient centricity
Reducing patient burden in clinical trials – especially for rare diseases – is a key objective for drug developers. Decentralized…
-
Overcoming challenges in orphan drug development: From clinical trials to market
Developing treatments for rare diseases, known as orphan drugs, presents a range of unique challenges from the outset, from limited…
-
How collaborative partnerships are driving progress in transformative cell and gene therapies (CGTs)
Cell and gene therapies (CGTs) are currently at the heart of dynamic trends in the pharma sector. While oncology remains…
-
Obesity-related liver conditions: Understanding treatment options
The prevalence of obesity has more than doubled since 1990, with nearly one billion people living with obesity globally in…
-
Unmatched quality in pharmaceutical logistics: Why it matters
Ensuring the integrity of pharmaceutical products is one of the most complex challenges in global healthcare today. From temperature-sensitive biologics…
-
Artificial intelligence is making clinical supply chains more efficient and more sustainable: here’s how
The pharmaceutical industry is in the midst of a digital revolution; technology investments and data-driven decision-making are constantly on the…
-
How CNS researchers are handling clinical trial turbulence
The field of central nervous system (CNS) drug development is awash with activity. Data from GlobalData’s drugs database, as of…
-
Navigating the complexities of sustainable specialty pharma supply chains
The pharmaceutical world is changing. Sales of personalised therapies, for example, will skyrocket from $8 billion in 2022 to a…